

Necitumumab SQUIRE


PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



No QoL benefit

Serious and disabling adverse effects



Other adjustments



Necitumumab SQUIRE

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

1




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
 Therapeutic Indication: Locally advanced or metastatic EGFR-expressing squamous NSCLC without prior ChT  
 Experimental Arm: Necitumumab + Gemcitabine + cisplatin  
 Control Arm: Gemcitabine + cisplatin

